{"schema_version":"secwatch.filing_event.v1","accession":"0001645113-23-000050","form_type":"8-K","ticker":"NVCR","cik":"0001645113","company_name":"NovoCure Ltd","filed_at":"2023-11-28T23:59:59+00:00","discovered_at":"2026-05-14T18:03:29.924087+00:00","generated_at":"2026-06-07T21:02:38.133823+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Novocure announces $60M cost-cutting plan, cuts 200 jobs (13% of workforce)","bullets":["Reduction in residual operating expenses of ~$60M; includes 200 job cuts (13% of staff).","One-time restructuring charge of ~$7M expected in Q4 2023.","Pivots resources to launch readiness for metastatic NSCLC Tumor Treating Fields therapy.","Plans two Phase 3 readouts in 2024: METIS (brain mets NSCLC) and PANOVA-3 (pancreatic).","Prioritizes clinical trials TRIDENT, KEYNOTE D58, LUNAR-2 for greatest value."],"urls":{"canonical":"https://secwatch.observer/filing/0001645113-23-000050","json":"https://secwatch.observer/filing/0001645113-23-000050.json","markdown":"https://secwatch.observer/filing/0001645113-23-000050.md","text":"https://secwatch.observer/filing/0001645113-23-000050.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1645113/000164511323000050/0001645113-23-000050-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1645113/000164511323000050/nvcr-20231128.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T21:02:38.133823+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}